Nolato (NOLA) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
21 May, 2026Executive summary
Q1 2026 sales reached SEK 2,357 million, with 3% organic growth adjusted for currency, despite volatile geopolitical and currency headwinds.
EBITA was SEK 260 million, with a stable margin of 11.0%, though profit after tax declined to SEK 181 million and EPS to SEK 0.67.
Cash flow from operating activities improved to SEK 225 million, reflecting operational efficiency.
Strong financial position maintained, with net financial liabilities/EBITDA at 0.5x and equity/assets ratio at 60%.
Ongoing acquisition strategy and global expansion supported by robust balance sheet.
Financial highlights
Net sales were SEK 2,357 million (down from SEK 2,453 million year-over-year), with 3% organic growth adjusted for currency.
EBITA was SEK 260 million (down from SEK 271 million), and EBITA margin remained at 11.0%.
Profit after tax was SEK 181 million, and earnings per share were SEK 0.67, both slightly lower than the prior year.
Cash flow from operating activities increased to SEK 225 million, and cash flow after investments was SEK 32 million (up from -SEK 136 million).
Net financial liabilities to EBITDA remained low at 0.5x.
Outlook and guidance
Anticipates 5%-10% increase in raw material costs in the near term, with most impact in Q2 and some spillover into Q3.
Margin impact from input cost inflation expected to normalize by Q3 as price increases are passed to customers with a 3-4 month lag.
CapEx guidance for 2026 remains SEK 650–700 million.
Expansion projects in Hungary, Poland, and Malaysia are progressing as planned, with commercial volumes in Hungary expected from end of Q2.
Focus on innovation, sustainability, and intensified M&A agenda supported by strong financial position.
Latest events from Nolato
- Q4 sales rose 2% adjusted for currency, with EBITA margin up and Medical Solutions leading growth.NOLA
Q4 202511 May 2026 - Q2 EBITA margin hit 10.0% with strong cash flow, despite a 2% sales drop.NOLA
Q2 20243 Feb 2026 - Q3 2024 delivered higher sales, margin gains, and strong cash flow despite automotive headwinds.NOLA
Q3 202418 Jan 2026 - Q4 profit and margin surged on 5% sales growth, with strong cash flow and stable dividend.NOLA
Q4 202423 Dec 2025 - Raised financial targets and sustainability focus drive global growth and innovation.NOLA
CMD 20252 Dec 2025 - EBITA up 14% to SEK 271m, with margin gains and Medical Solutions driving growth.NOLA
Q1 202524 Nov 2025 - Q2 2025 saw 4% organic sales growth and margin gains, led by Medical Solutions and expansion.NOLA
Q2 202516 Nov 2025 - Q3 saw 20% EBITA growth, margin gains, and global expansion, with strong financials and investments.NOLA
Q3 202529 Oct 2025